Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) (CaNI) for advanced renal cell carcinoma with variant histology (aRCCVH).
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Dana-Farber Cancer Institute, Emory University, Harvard University, Dana-Farber/Harvard Cancer Center, Beth Israel Deaconess Medical Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Moores Cancer Center, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Exelixis
OpenAlex ID: W3169988899